menu
menu
Recent reviews and studies have shed light on the prevalence of HPV-negative cervical cancers and precancers, challenging previous assumptions about their rarity. Patients with HPV-negative tumors tended to be older and more frequently diagnosed with non-squamous types of tumors. These tumors were often identified at more advanced stages and were more likely to have lymph node metastases, emphasizing the need for vigilant screening and diagnostic strategies to effectively manage and treat HPV-negative cervical cancers and precancers.
To address this gap, ASCP developed four microlearning courses to help pathologists and laboratory professionals enhance their knowledge and skills to ensure that all patients with HPV-negative cervical cancer and precancers receive accurate diagnoses and appropriate care.
On February 22, 2022, ASCP CEO Blair Holladay, PhD, MASCP, SCT(ASCP)CM, moderated a roundtable discussion on cervical cancer screening strategy in the U.S. Dr. Holladay and a multi-disciplinary panel of experts featuring cytopathologists and Ob/Gyns used patient case-based reviews to address the following topics:
Adrienne Stevenson, MD, OBGYN
Darren Wheeler, MD, FASCP, Pathologist and Regional Anatomic Pathology Medical Director, West & South East, Quest Diagnostics & AmeriPath, Inc.
Amita Murthy, MD, MPH, OBGYN at NYC Department of Health
Diane D. Davey, MD, Associate Dean, Graduate Medical Education, Professor of Pathology at the University of Central Florida